Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-12-12 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about the authorized entrusted financial management, amounts, product types, expected yields, risk control measures, and a summary of ongoing and matured entrusted financial products. The document is a disclosure about the company's use of idle raised funds for financial management purposes, which relates to capital management and financing activities. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement of a report publication. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and use of capital raised.
2024-12-12 Chinese
关于使用自有闲置资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It details the authorization, amounts, types of financial products purchased, risk control measures, and related disclosures. The document is a regulatory disclosure about the company's capital management activities, specifically about entrusted financial management and investment of idle funds. It does not contain financial statements, earnings data, or management discussion of results. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is not a certification or a voting result announcement. The document is a capital/financing update related to the company's use of funds and investment activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is about 4638 characters, which is sufficient for a detailed announcement but not a full financial report.
2024-12-08 Chinese
关于使用自有闲置资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It details the authorization, amounts, types of financial products purchased, risk controls, and related disclosures. The document is relatively short (4074 characters) and focuses on disclosing a specific financing activity related to the company's use of idle funds for investment in low-risk financial products. There are no financial statements, no quarterly or annual results, no audit opinions, no management discussions of financial results, no legal proceedings, no merger or acquisition information, and no voting results. The content is an update on the company's capital usage and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-11-12 Chinese
高级管理人员辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel, specifically the vice general manager, including details about the resignation date, shareholding, and impact on the company. It does not contain financial data, audit information, or report content. It is clearly about management changes and their implications. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management resignation, confirming this classification.
2024-11-03 Chinese
关于使用自有闲置资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types of financial products, expected yields, risk management, and internal controls. The document is a disclosure about capital management activities, specifically the use of idle funds for entrusted financial management. It does not contain financial statements, audit opinions, or earnings data. It is not a report publication announcement since it contains substantive details about the transactions and risk controls. The content aligns with updates on company fundraising, financing activities, or capital structure changes, which fits the Capital/Financing Update category (CAP). The document length is 4298 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2024-10-30 Chinese
第四届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board regarding the approval of the company's 2024 third quarter report. It references the actual quarterly report being disclosed on the Beijing Stock Exchange information platform with a separate announcement number (2024-118). The current document itself does not contain the financial data or substantive analysis of the quarterly report but merely announces the supervisory board's approval of that report. The document length is short (846 characters) and fits the pattern of an announcement rather than the report itself. Therefore, according to the 'Menu vs Meal' rule, this is not the quarterly report (IR) but an announcement related to it. The best fitting category is Regulatory Filings (RNS), as it is a formal regulatory announcement about the supervisory board meeting and approval of the quarterly report, without the report content itself.
2024-10-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.